This Month in Psychopharmacology

Highlights from 2024 NEI Synapse: We Didn’t Write the Rx: A Guide to the Pros and Cons of Complementary and Alternative Medicine

Complementary health approaches are commonly used by patients seeki...

Read More

Metabolic Markers Tied to Increased Risk of Mental Disorders

A recent study examined whether the biomarkers of carbohydrate, lip...

Read More

CDC Issues New Guidance on Identifying, Responding to Suicide Clusters

Responding to suicide clusters requires a comprehensive and proacti...

Read More

Highlights from 2023 NEI Congress: Scientific Poster Session Winners

The 2023 NEI Congress Scientific Poster Session was held on Friday,...

Read More

Suicide Risk Among Patients Hospitalized With Psychiatric Illness

Fifteen to thirty percent of patients with a history of concussion ...

Read More

Meet DEA Training Requirements

Activities available as part of NEI Membership can fulfill the new,...

Read More

Updates to DSM-5-TR Criteria and Text

The American Psychiatric Association (APA) released DSM-5-TR™ Updat...

Read More

CDC Estimates Suicides in U.S. Reached All-Time High in 2022

Provisional data released by the Center for Disease Control and Pre...

Read More

World Schizophrenia Day: Education and Tool for Providers

The high rates of treatment resistance, relapse rates, and incidenc...

Read More

2023 NEI Synapse: Biggest Mistakes in Psychopharm

On Saturday, April 1, we rounded out a fantastic 2023 NEI Synapse m...

Read More

FDA Approves First Over-the-Counter Naloxone Nasal Spray

The U.S. Food and Drug Administration approved naloxone hydrochlori...

Read More

The Future of Psychopharmacology

It is an incredible time in terms of the development of new psychop...

Read More